High technological innovation

DotBodies use large-scale screening and isolation technology, with good affinity, thermal stability and high expression. And the sustained-release technology of nanobodies can prolong the duration of effect.

New drug treatment

Compared with the traditional intravitreal needle injection, the use of needle-free injection of DotBodies can greatly reduce the pain of patients and effectively reduce the risk of complications caused by eye injections.

Stable process and low cost

Mature E. coli expression system, low cost and stable process.

According to CICC International Consulting, along with the milestone progress in the field of antibody engineering and antibody biology, bispecific antibody technology has been continuously innovated and made breakthroughs. It is expected that the global bispecific antibody drug market will grow to 18.4 billion US dollars by 2025.

The global diabetic retinopathy market is expected to grow at a CAGR of 6.4% to reach USD 13.8 billion by 2030. The market size will continue to expand due to increasing patient awareness, rising healthcare spending, and an aging population.

The market size of wet AMD, DME, and other indications is still not large, because there are fewer drugs to choose from. In the future, with the deepening of China's population aging and the launch of domestic manufacturers' drugs, wet AMD and DME are expected to become the fastest growing areas in China's ophthalmic indication market, with a CAGR of more than 40%.